GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Gross Profit

AngioDynamics (AngioDynamics) Gross Profit : $162.5 Mil (TTM As of Feb. 2024)


View and export this data going back to 2004. Start your Free Trial

What is AngioDynamics Gross Profit?

AngioDynamics's gross profit for the three months ended in Feb. 2024 was $35.9 Mil. AngioDynamics's gross profit for the trailing twelve months (TTM) ended in Feb. 2024 was $162.5 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. AngioDynamics's gross profit for the three months ended in Feb. 2024 was $35.9 Mil. AngioDynamics's Revenue for the three months ended in Feb. 2024 was $75.2 Mil. Therefore, AngioDynamics's Gross Margin % for the quarter that ended in Feb. 2024 was 47.70%.

AngioDynamics had a gross margin of 47.70% for the quarter that ended in Feb. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of AngioDynamics was 57.64%. The lowest was 49.26%. And the median was 52.89%.

Warning Sign:

AngioDynamics Inc gross margin has been in long-term decline. The average rate of decline per year is -1.9%.


AngioDynamics Gross Profit Historical Data

The historical data trend for AngioDynamics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Gross Profit Chart

AngioDynamics Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 156.00 150.27 156.79 165.73 174.25

AngioDynamics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.50 46.36 40.06 40.26 35.86

Competitive Comparison of AngioDynamics's Gross Profit

For the Medical Instruments & Supplies subindustry, AngioDynamics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Gross Profit distribution charts can be found below:

* The bar in red indicates where AngioDynamics's Gross Profit falls into.



AngioDynamics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

AngioDynamics's Gross Profit for the fiscal year that ended in May. 2023 is calculated as

Gross Profit (A: May. 2023 )=Revenue - Cost of Goods Sold
=338.752 - 164.506
=174.2

AngioDynamics's Gross Profit for the quarter that ended in Feb. 2024 is calculated as

Gross Profit (Q: Feb. 2024 )=Revenue - Cost of Goods Sold
=75.182 - 39.321
=35.9

Gross Profit for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $162.5 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

AngioDynamics's Gross Margin % for the quarter that ended in Feb. 2024 is calculated as

Gross Margin % (Q: Feb. 2024 )=Gross Profit (Q: Feb. 2024 ) / Revenue (Q: Feb. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=35.9 / 75.182
=47.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


AngioDynamics  (NAS:ANGO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

AngioDynamics had a gross margin of 47.70% for the quarter that ended in Feb. 2024 => Durable competitive advantage


AngioDynamics Gross Profit Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics (AngioDynamics) Business Description

Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.
Executives
Lorinda Burgess director 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff director C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea officer: SVP/GM, VIT C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel officer: SVP Global Operations and R&D 400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini officer: SVP International C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge officer: SVP and General Counsel 14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer director, officer: President and CEO COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson director
Chad Thomas Campbell officer: SVP/GM, Vascular Access 140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan officer: SVP Quality and Regulatory ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig officer: SVP and General Counsel C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould director 247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher officer: SVP and GM of Oncology 14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner officer: EVP and CFO C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421